Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | CTSA | P10619 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31384302 | 1.00 | KCNK3 (0.57) | KCNK3KCNK9CTSAKDM4ECYP1A2 | |
| SCHEMBL2993048 | 0.85 | KDM4E (0.49) | KCNK3KCNK9CTSAKDM4ECYP1A2 | |
| SCHEMBL31354767 | 0.85 | KCNK3 (0.58) | KCNK3KCNK9CTSAKDM4ELOX | |
| SCHEMBL1515813 | 0.85 | KCNK3 (0.58) | KCNK3KCNK9CTSAKDM4ELOX | |
| SCHEMBL13570731 | 0.83 | KCNK3 (0.57) | KCNK3KCNK9CTSAKDM4ELOX | |
| SCHEMBL11817959 | 0.83 | KCNK3 (0.53) | KCNK3KCNK9CTSALOXLOXL2 | |
| SCHEMBL30859586 | 0.82 | CTSA (0.56) | KCNK3KCNK9CTSAKDM4EALDH1A1 | |
| SCHEMBL2798344 | 0.82 | CTSA (0.56) | KCNK3KCNK9CTSAKDM4EALDH1A1 | |
| SCHEMBL25166967 | 0.82 | KDM4E (0.49) | KCNK3KCNK9CTSAKDM4ECYP1A2 | |
| SCHEMBL29195058 | 0.81 | CTSA (0.53) | KCNK3KCNK9CTSAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10058550-B2 | Methods of treating heart failure | AMGEN INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | KCNK3 665/4885KCNK9 1274/4885CTSA 3205/4885 |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | KCNK3 544/4885KCNK9 219/4885CTSA 4168/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | KCNK3 1356/4885KCNK9 1371/4885CTSA 3324/4885 |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | KCNK3 4466/4885KCNK9 4665/4885CTSA 3011/4885 |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | KCNK3 619/4885KCNK9 1173/4885CTSA 4725/4885 |
| US-10058550-B2 | Methods of treating heart failure | FABP3, TNNI3, APLNR | KCNK3 295/4885KCNK9 354/4885CTSA 4180/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | KCNK3 4466/4885KCNK9 4665/4885CTSA 3011/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | KCNK3 544/4885KCNK9 219/4885CTSA 4168/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | KCNK3 295/4885KCNK9 354/4885CTSA 4180/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | KCNK3 597/4885KCNK9 1122/4885CTSA 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.